These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 16595487

  • 1. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer.
    Prévost S, Boucher L, Larivée P, Boileau R, Bénard F.
    J Nucl Med; 2006 Apr; 47(4):559-65. PubMed ID: 16595487
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 3. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW, Na JO, Kang DY, Lee SY, Lee SM.
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
    Trister AD, Pryma DA, Xanthopoulos E, Kucharczuk J, Sterman D, Rengan R.
    Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
    [Abstract] [Full Text] [Related]

  • 5. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
    Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK.
    Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [Abstract] [Full Text] [Related]

  • 9. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
    Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K.
    J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K, Okita R, Saisho S, Yukawa T, Maeda A, Nojima Y, Nakata M.
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer.
    Zhang H, Wroblewski K, Pu Y.
    Acta Radiol; 2012 Jun 01; 53(5):561-8. PubMed ID: 22661603
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H.
    Nucl Med Commun; 2012 Jun 01; 33(6):613-20. PubMed ID: 22407127
    [Abstract] [Full Text] [Related]

  • 13. The role of 18F-fluorodeoxyglucose uptake of bone marrow on PET/CT in predicting clinical outcomes in non-small cell lung cancer patients treated with chemoradiotherapy.
    Lee JW, Seo KH, Kim ES, Lee SM.
    Eur Radiol; 2017 May 01; 27(5):1912-1921. PubMed ID: 27590191
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H, Li B.
    J Nucl Med; 2014 Oct 01; 55(10):1584-90. PubMed ID: 25214640
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y, Lin WY, Kao CH, Yen KY, Chen SW, Yeh JJ.
    Anticancer Res; 2012 Nov 01; 32(11):5087-91. PubMed ID: 23155285
    [Abstract] [Full Text] [Related]

  • 19. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
    Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V.
    J Clin Oncol; 2004 Aug 15; 22(16):3255-60. PubMed ID: 15310769
    [Abstract] [Full Text] [Related]

  • 20. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F.
    J Nucl Med; 2013 Aug 15; 54(8):1244-50. PubMed ID: 23674577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.